Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Phase 3 Completed 166 enrolled Gynecologic Oncology Group Eastern Cooperative Oncology Group · collab National Cancer Institute (NCI) · collab

RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide alone is more effective than ifosfamide plus paclitaxel in treating patients with cancer of the uterus. PURPOSE: Randomized phase III trial to compare the effectiveness of ifosfamide with or without paclitaxel in treating patients with advanced, refractory, or recurrent cancer of the uterus.

Timeline

Start: 1997-11
Primary completion: 2007-02
Completion: —

Publications

Results Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10;25(5):526-31. doi: 10.1200/JCO.2006.06.4907.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ifosfamide	Small molecule	1.6 g	Intravenous
Subject	Ifosfamide	Small molecule	2 g	Intravenous
Subject	Paclitaxel	Small molecule	135 mg/m2	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Summary

Timeline

Publications

Drugs

Indications